Can Eli Lilly’s Two-Drug Obesity Treatment Justify Its $1 Trillion Valuation?

Eli Lilly presents mid-stage eloraTZP data September 30, and LLY stock near $1,152 with a $1 trillion market cap leaves no room for a weak result.

Novo Nordisk's GLP-1 franchise faces headwinds while Viking Therapeutics' VK2735 looms; a convincing eloraTZP win raises the bar for both rivals.

Bearish options positioning shows put/call ratios hitting 4.67 for October 9 expiry, signaling Wall Street is hedging hard against disappointment.

Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Eli Lilly didn't make the cut. Enter your email to see the names that beat LLY. The report is free. Enter your email and see if any of your stocks made the cut.

Eli Lilly ( NYSE:LLY ) presents mid-stage data on eloraTZP, a combination of eloralintide and tirzepatide, at a European Association for the Study of Diabetes symposium on September 30.

An earlier Phase 1 study hinted the pairing could deepen weight loss beyond tirzepatide alone. The mid-stage trial enrolls a larger group of adults with obesity or overweight and type 2 diabetes.

The stock trades near $1,152.44 on obesity-franchise expectations that leave little room for disappointment.

Watch four metrics: weight loss magnitude, dose arms, tolerability, and discontinuation rates. The combination must separate from each individual component, not just placebo, or the strategic rationale weakens.

Discontinuations matter because tolerability drives persistence and persistence drives revenue. A combo that adds modest weight loss but pushes more patients off therapy is a hollow win.

Mounjaro and Zepbound delivered $14.87 billion in the second quarter, with Mounjaro up 91% year over year. That scale outpaces Novo Nordisk ( NYSE:NVO ), whose GLP-1 franchise faces headwinds.

Viking Therapeutics ( NASDAQ:VKTX ) poses a smaller but real threat with VK2735. A convincing eloraTZP result would raise the bar for both competitors.

24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now . Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.

The report is free, and you can see why we think each stock is a top investment today.

Lilly trades at a forward earnings multiple of 24x against a trailing 38x, and a market capitalization near $1.01 trillion. Options markets show the caution: put/call ratios of 2.33 for the October 2 expiration and 4.67 for October 9.